Article Menu

Export Article

More by Authors Links

Article Data

  • Views 3228
  • Dowloads 112

Case Report

Open Access

Reversible peripartum cardiomyopathy in a triplet pregnancy

  • EDVARD GALIĆ1
  • DARIO GULIN1
  • KREŠIMIR KORDIĆ1
  • BERIVOJ MIŠKOVIĆ1
  • OLIVER VASILJ1
  • JOZICA ŠIKIĆ1

1Department of Cardiovascular Diseases University Hospital “Sveti Duh” School of Medicine, University of Zagreb

DOI: 10.22514/SV102.122015.16 Vol.10,Issue 2,December 2015 pp.216-223

Published: 14 December 2015

*Corresponding Author(s): DARIO GULIN E-mail: dariogulin@gmail.com

PDF (1.86 MB) View Full-text

Abstract

Peripartum cardiomyopathy (PPCM) is a rare form of dilated cardiomyopathy that occurs in previously healthy women in the last month of pregnancy and up to several months after delivery. The incidence of PPCM is low, but its morbidity and mortality rate are high, with a substantial risk of poor outcome of the pregnancy. Patients who have recovered from PPCM run a high risk of reoccurrence in subsequent pregnancies. In this case report we present a 32-year old female patient who developed acute heart failure (HF) associated with significantly reduced systolic function due to PPCM soon after a delivery of triplets. Treatment was immediately initiated in the intensive coronary unit with oxygen-therapy, loop diuretics, aldosterone blockers, beta blockers, angiotensin-converting enzyme (ACE) inhibitors and bromocriptine. During the follow up period, a year and a half after delivery, a complete recovery of systolic function was observed with no residual symptoms.

Keywords

dilated cardiomyopathy, triplet pregnancy, peripartum period

Cite and Share

EDVARD GALIĆ,DARIO GULIN,KREŠIMIR KORDIĆ,BERIVOJ MIŠKOVIĆ,OLIVER VASILJ,JOZICA ŠIKIĆ. Reversible peripartum cardiomyopathy in a triplet pregnancy. Signa Vitae. 2015. 10(2);216-223.

URL:

https://www.signavitae.com/articles/10.22514/SV102.122015.16

References

1. Pearson GD, Veille JC, Rahimtoola S. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000;283:1183-8.

2. Hibbard JU, Lindheimer M, Lang R. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol 1999;94:311-6.

3. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, Shotan A. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation

2005;111(16):2050-5.

4. Ntusi N, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy a systematic review. Int J Cardiol 2009;131:168-79.

5. Lindenfeld J, Albert NM, Boehmer JP. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:475-539.

6. Hilfiker KD, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J 2015;36(18):1090–7.

7. Bozkurt B, Villaneuva FS, Holubkov R, Tokarczyk T, Alvarez RJ Jr, MacGowan GA, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 1999;34(1):177–80.

8. Carlin AJ, Alfirevic Z, Gyte GM. Interventions for treating peripartum cardiomyopathy to improve outcomes for women and babies. Cochrane Database Syst Rev 2010;(9):CD008589.

9. Grewal J, Siu SC, Ross H, Mason J, Balint OH, Sermer M, et al. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol 2009;55:45–52.

10. Patel H, Madanieh R, Kosmas CE, Vatti SK, Vittorio TJ. Reversible Cardiomyopathies. Clin Med Insights Cardiol 2015;9(2):7–14.

Submission Turnaround Time

Top